Source comparison
CJC-1295 no DAC & Ipamorelin Fat Loss Results Timeline Expect: Clinical vs Anecdotal Comparison
Time to First Visible Changes 4–6 weeks at 100mcg CJC/200mcg Ipa doses 3–8 weeks (highly variable based on adherence) Expect week 4–6 if protocol and diet are locked in Peak Fat Loss Window Weeks 8–16, 2–4% body fat reduction Weeks 10–14, 1.5–3.5% body fat red
This comparison does not assign a generated winner or score.
- Time to First Visible Changes
- 4–6 weeks at 100mcg CJC/200mcg Ipa doses
- 3–8 weeks (highly variable based on adherence)
- Expect week 4–6 if protocol and diet are locked in
- Peak Fat Loss Window
- Weeks 8–16, 2–4% body fat reduction
- Weeks 10–14, 1.5–3.5% body fat reduction
- Consistent with GH receptor dynamics. Matches clinical data
- Receptor Sensitivity Decline
- Documented after 12–16 weeks continuous use
- Anecdotal plateau reports at weeks 12–20
- Cycling 8–12 weeks on, 4 weeks off preserves sensitivity
- Dependence on Caloric Deficit
- Absolute requirement. No fat loss at maintenance or surplus
- Mixed reports (some claim recomp at maintenance)
- Fat loss requires deficit; recomp only occurs in novice or detrained populations
- Injection Timing Impact
- Pre-bed dosing produced 22% higher overnight GH AUC vs random timing
- Most users dose pre-bed or fasted AM; timing compliance high
- Timing is non-negotiable. Random dosing cuts efficacy by 30–40%
- Side Effect Frequency
- Water retention (12–18% of subjects), transient flushing (8–10%)
- Water retention and hunger spikes commonly reported
- Ipamorelin is ghrelin-mimetic. Hunger is expected; hydration mitigates retention